Concepedia

Edward A. Kesicki

EA

19

Publications

1.5K

Citations

17

H-Index

1993

Active since

Affiliations

Eli Lilly (United States)(Current)

Infectious Disease Research Institute

EKOS Corporation

AbbVie (United States)

Molecular Oncology (United States)

Edward A. Kesicki is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and natural sciences.

Top concepts

Publications per year

1993–2021

19

Publications

19

Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 Acetylome

Brian T. Weinert, Takeo Narita, Shankha Satpathy et al. · Cell · 2018 · 511 citations · Full text

, , +3

DNA-Dependent Protein Kinase Is a Molecular Target for the Development of Noncytotoxic Radiation–Sensitizing Drugs

Eric T. Shinohara, Ling Geng, Jiahui Tan et al. · Cancer Research · 2005 · 134 citations · Full text

, , +19

Validation of the Essential ClpP Protease in Mycobacterium tuberculosis as a Novel Drug Target

Juliane Ollinger, Theresa O’Malley, Edward A. Kesicki et al. · Journal of Bacteriology · 2011 · 130 citations · Full text

Phenylboronic Acid−Salicylhydroxamic Acid Bioconjugates. 1. A Novel Boronic Acid Complex for Protein Immobilization

Mark L. Stolowitz, Clarence Ahlem, Karin A. Hughes et al. · Bioconjugate Chemistry · 2001 · 115 citations

DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer.

Adam Kashishian, Heather Douangpanya, Darcey Clark et al. · PubMed · 2003 · 92 citations

, , +15

Rows per page

1–5 of 19